Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
Verastem, Inc. (VSTM)
Last verastem, inc. earnings: 10/29 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
verastem.com
Company Research
Source: Business Wire
Company Reports $3.0 Million in Net Product Revenues from COPIKTRA®; Raises Product Revenue Guidance for 2019Cash, Cash Equivalents and Short-Term Investments of $187.3 Million as of June 30, 2019Company to Host Conference Call Today at 4:30 PM ET BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM), operating as Verastem Oncology (or “the Company”), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today reported financial results for the three months ended June 30, 2019, and provided an overview of recent accomplishments and clinical development progress for duvelisib (COPIKTRA®).“With the third full quarter of the COPIKTRA launch now complete, including the first full quarter of the follicular lymphoma (FL) marketing campaign, net sales are up 81% quarter-over-quarter,” said Dan Paterson, President and Chief Operating Officer of Verastem Oncology. “We have begun to see early signs that our physician educ
Show less
Read more
Impact Snapshot
Event Time:
VSTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VSTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VSTM alerts
High impacting Verastem, Inc. news events
Weekly update
A roundup of the hottest topics
VSTM
News
- Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical OfficerBusiness Wire
- Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner [Yahoo! Finance]Yahoo! Finance
- GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual MeetingPR Newswire
VSTM
Earnings
- 3/14/24 - Miss
VSTM
Sec Filings
- 4/12/24 - Form DEF
- 4/9/24 - Form 8-K
- 4/8/24 - Form 4
- VSTM's page on the SEC website